Ablexis inks licensing deal with Memorial Sloan Kettering

Agreement grants rights to research, develop and commercialize antibodies generated using AlivaMab Mouse platform
| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
SAN DIEGO—Ablexis LLC, a biopharmaceutical company focused on licensing its AlivaMab Mouse technology for antibody drug discovery, has announced a license agreement with Memorial Sloan Kettering Cancer Center. The license grants Memorial Sloan Kettering rights to research, develop and commercialize—with rights to sub-license—certain AlivaMab antibodies against a specific target.
 
The antibodies were generated by the Tri-Institutional Therapeutics Discovery Institute Inc. under a non-exclusive license of AlivaMab Mouse announced in January 2017. Under this new license, Ablexis could receive clinical development and approval milestones, and a running revenue share of sales of products derived from the AlivaMab antibodies.
 
“The AlivaMab Mouse is an increasingly validated platform for generating antibodies with qualities desirable in a potential therapeutic,” said Dr. Larry Green, CEO of Ablexis. “This agreement with Memorial Sloan Kettering exemplifies the speed and value-add that the AlivaMab Mouse can bring to a therapeutic antibody discovery program.”
 
The AlivaMab Mouse is designed to enable and optimize the efficient discovery and development of the next generation of human therapeutic antibodies. The platform has been validated for antibody drug discovery by Ablexis and partners in various formats—including regular antibodies, bispecifics and chimeric antigen receptor T cell therapies—and for a range of applications, such as:
  • Sequence diverse panels of monoclonal antibodies (mAbs)
  • Epitope diverse panels of mAbs
  • Challenging targets such as G-protein-coupled receptors
  • Challenging design goals such as IC50 values of very low picomolar levels.
Ablexis has non-exclusively licensed the AlivaMab Mouse technology to multiple companies, including global pharmaceutical companies, public and private biotechnology companies and other entities.

Related Topics

Published In

Volume 14 - Issue 11 | November 2018

November 2018

November 2018 Issue

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Surface rendering of two interacting proteins (green and peach) bound together by a small molecule ligand at their interface, illustrating a protein-ligand binding event.
Learn how molecular dynamics, AI-aided design, and structural insights combine to reshape how therapeutic proteins are created, validated, and optimized.
Stem cells are shown as clear, purple, and blue spheres against a dark blue and black background.
Human-relevant, ready-to-use stem cell models are reshaping drug discovery, toxicity testing, and personalized medicine.
Characterizing lipid nanoparticles for RNA therapeutic development
Integrated multiomics and advanced nanoparticle analytics are improving how researchers perform RNA delivery, increasing therapeutic success.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue